Mucospas (Ambroxol Hydrochloride, Clenbuterol Hydrochloride)

Ambroxol Hydrochloride and Clenbuterol Hydrochloride, the active ingredients in Mucospas, are mucolytic and β2‑adrenergic agonist drugs presented as an oral formulation for oral use. They are used to relieve mucus congestion and bronchospasm in patients with acute or chronic respiratory conditions.

GNH USA supplies Mucospas as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Mucospas, containing a mucolytic and a β2‑adrenergic agonist, is indicated for disorders of the respiratory tract that involve mucus hypersecretion or bronchoconstriction.

Acute bronchitis: reduces mucus viscosity and improves cough clearance. Chronic bronchitis (COPD): helps clear sputum and eases breathing. Asthma exacerbations: provides bronchodilation to relieve bronchospasm. Bronchospasm associated with respiratory infections: relaxes airway smooth muscle and facilitates mucus clearance.

Common Side Effects: - Nausea: mild gastrointestinal upset. - Headache: transient cranial discomfort. - Tremor: fine muscle shaking, especially in the hands. - Palpitations: awareness of heartbeat acceleration. - Dry mouth: reduced salivation. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Cardiac arrhythmia: irregular heart rhythm requiring medical attention. - Severe bronchospasm: paradoxical worsening of airway constriction. - Hypokalemia: low blood potassium levels, may cause muscle weakness. - Anaphylaxis: acute allergic reaction with rash, swelling, and airway compromise. - Tachycardia: sustained rapid heart rate. - Hypertension: elevated blood pressure beyond normal range.

Before initiating therapy, clinicians should evaluate patient-specific factors and monitor for adverse reactions.

Assess renal and hepatic function: adjust use if organ impairment is present. Monitor cardiac status: avoid in uncontrolled heart disease. Use caution in hyperthyroidism: β2‑agonists may exacerbate symptoms. Avoid in uncontrolled hypertension: risk of further blood pressure rise. Check for known hypersensitivity to either component. Store at ambient temperature: keep in the original pack, protect from moisture.

Mucospas may interact with other medicines that affect cardiovascular or electrolyte balance.

Major Interactions (Avoid): - Beta‑blockers: antagonize bronchodilator effect. - MAO inhibitors: increase risk of hypertensive crisis. - Potassium‑wasting diuretics: may precipitate hypokalemia. - Other sympathomimetics: additive cardiovascular stimulation.

Moderate Interactions (Monitor Closely): - Anticholinergics: may enhance anticholinergic side effects. - Theophylline: increased risk of tachyarrhythmia. - ACE inhibitors: potential for additive hypotensive effect. - NSAIDs: may blunt bronchodilator response.